Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1472

Sort by

Sort Order Select

Journal Articles

Minorities Do Not Have Worse Outcomes for Diffuse Large B Cell Lymphoma (DLBCL) If Optimally Managed

Bei Hu, MD, Tommy Chen, Danielle Boselli, MS, Rupali Bose, MS, MBA, James T. Symanowski, PhD, Derek Raghavan, MDPhDFACP,FRACP, Amy Soni, MD, Steven I Park, MD, Belinda R Avalos, MD, Edward A Copelan, Ryan Jacobs, MD, Nilanjan Ghosh, MD PhD

Blood (2019) 134 (Supplement_1): 425.

https://doi.org/10.1182/blood-2019-123998

Published: 2019

Journal Articles

Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 460.

https://doi.org/10.1182/blood-2019-121870

Published: 2019

Journal Articles

Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia

Abhishek Maiti, MBBS, Caitlin R. Rausch, PharmD, Jorge E. Cortes, MD, Naveen Pemmaraju, MD, Naval G. Daver, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Gautam M. Borthakur, MD, Kiran Naqvi, MDMPH, Maro Ohanian, DO, Nicholas J. Short, MD, Yesid Alvarado, MD, Christopher B. Benton, MD, Tapan M. Kadia, MD, Koichi Takahashi, MD, Musa Yilmaz, MD, Nitin Jain, MD, Steven M. Kornblau, MD, Koji Sasaki, MD, Michael Andreeff, MD PhD, Prithviraj Bose, MD, Alessandra Ferrajoli, MD, Ghayas C. Issa, MD, Elias Jabbour, MD, Lucia Masarova, MD, Michael E. Rytting, MD, Philip A. Thompson, MBBS, Sa A Wang, MD, Sergej Konoplev, Zhining Chen, Maitrayee Goswami, Rita Maduike, Julio A Guerrero, RN, Qi Zhang, PhD, Antonio Cavazos, Helen Ma, MS, Carol A. Bivins, RN, Allison Wade, Shadiat L Adewale, Susan Tse, Robin Thomas, Kenneth Vaughan, RN, Sherry A. Pierce, BSN, BA, Jing Ning, PhD, Wei Qiao, PhD, John S. Welch, MD PhD, Keyur P. Patel, MBBS, PhD, Hagop M. Kantarjian, MD, Marina Y Konopleva, MD PhD, Courtney D. DiNardo, MD MSc

Blood (2019) 134 (Supplement_1): 645.

https://doi.org/10.1182/blood-2019-128547

Published: 2019

Journal Articles

Outcomes of Patients with Acute Myeloid Leukemia with Myelodysplastic Are Dependent on Diagnostic Criteria and Therapy

Guillermo Montalban-Bravo, MD, Rashmi Kanagal-Shamanna, MD, Koji Sasaki, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Naval G. Daver, MD, Koichi Takahashi, MD, Courtney D. DiNardo, MD MSc, Elias Jabbour, MD, Gautam M. Borthakur, MD, Kiran Naqvi, MDMPH, Marina Y Konopleva, MD PhD, Sherry A. Pierce, BSN, BA, Carlos E. Bueso-Ramos, MD PhD, Keyur P. Patel, MBBS, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD

Blood (2019) 134 (Supplement_1): 647.

https://doi.org/10.1182/blood-2019-129373

Published: 2019

Journal Articles

Landscape of TP53 Mutations in MPN

Noushin Farnoud, PhD, Christopher Famulare, MS, Elli Papaemmanuil, PhD, Erin McGovern, BA, Juan Medina, MS, Juan E. Arango Ossa, BS, Raajit K. Rampal, MD PhD, Bing Li, MD, Ross L. Levine, MD, John Mascarenhas, MD, Rona Singer Weinberg, PhD, Minal A Patel, MPH, Ronald Hoffman, MD

Blood (2019) 134 (Supplement_1): 1681.

https://doi.org/10.1182/blood-2019-132014

Published: 2019

Journal Articles

VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRD) with or without Rivaroxaban Prophylaxis

Katrina M Piedra, PharmD, Hani Hassoun, MD, Larry W. Buie, PharmD, BCOP, FASHP, Sean M. Devlin, PhD, Jessica Flynn, BS, Malin Hultcrantz, MD PhD, Alexander M. Lesokhin, MD, Sydney X Lu, MD PhD, Sham Mailankody, MBBS, Urvi A Shah, MD, Eric L Smith, MD PhD, Ola Landgren, MD PhD, Neha Korde, MD, Tim J Peterson, PharmD

Blood (2019) 134 (Supplement_1): 1835.

https://doi.org/10.1182/blood-2019-124403

Published: 2019

Journal Articles

Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of CNS Relapse Treated in the Rituximab Era

Blood (2019) 134 (Supplement_1): 1619.

https://doi.org/10.1182/blood-2019-131435

Published: 2019

Journal Articles

Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes

Blood (2019) 134 (Supplement_1): 1711.

https://doi.org/10.1182/blood-2019-124978

Published: 2019

Journal Articles

WHO-Defined Chronic Myelomonocytic Leukemia-2 (CMML-2) Patients Rapidly Progress to AML Suggesting This Entity Represents a Transitory Clinical State

Anthony M. Hunter, MD, Najla Al Ali, M.Sc, David A Sallman, MD, Kendra L. Sweet, MD, Andrew T Kuykendall, MD, Chetasi Talati, MD, Alan F. List, MD, Jeffrey E. Lancet, MD, Rami S. Komrokji, MD, Eric Padron, MD

Blood (2019) 134 (Supplement_1): 1717.

https://doi.org/10.1182/blood-2019-131071

Published: 2019

Journal Articles

Choice of Hypomethylating Agent (HMA) for Initial Treatment Does Not Influence Outcome or Survival for Therapy-Related Myeloid Neoplasms (t-MN)

Charlene C. Kabel, PharmD, Debra A. Goldman, MS, Larry W. Buie, PharmD, BCOP, FASHP, Virginia M. Klimek, MD

Blood (2019) 134 (Supplement_1): 1718.

https://doi.org/10.1182/blood-2019-129129

Published: 2019

Journal Articles

RAS Mutations Are Independently Associated with Decreased Overall Survival and Event-Free Survival in Patients with AML Receiving Induction Chemotherapy

Brian J Ball, Meier Hsu, MS, Sean M. Devlin, PhD, Christopher Famulare, MS, Sheng F Cai, MDPhD, Andrew Dunbar, MD, Zachary D. Epstein-Peterson, MD, Kamal Menghrajani, MD, Jacob L Glass, MDPhD, Justin Taylor, MD, Aaron D Viny, MDMS, Aaron D Goldberg, MDPhD, Martin S. Tallman, MD, Eytan M. Stein, MD

Blood (2019) 134 (Supplement_1): 18.

https://doi.org/10.1182/blood-2019-125319

Published: 2019

Journal Articles

Feasibility of Outpatient High Dose Cytarabine in Patients with Acute Myeloid Leukemia

Chin-Hin NG, MD MRCP, FRCPATH, MCI, Xiaojuan Chen, BsN, MsN, Foong-Gwan Lee, BsN, Shi Hui Clarice Choong, MBBS, MRCP, Xiao-Shi Saw, BSc(Pharm), Lon-Wann Sai, MBBS, MRCP, Michelle Poon, MBBS, MRCP, FRCPATH, Hian Li Esther Hian Li Chan, MBBS, MRCP, FRCPATH, Melissa Ooi, MB BCh, BAO, MRCP(I), FRCPath, PhD, Yen Lin Chee, MBBS, FRCPATH, PhD, Yee Mei Lee, BsN, MsN, PhD

Blood (2019) 134 (Supplement_1): 2152.

https://doi.org/10.1182/blood-2019-129858

Published: 2019

Journal Articles

Implementation of Outpatient High-Dose Cytarabine (HiDAC) for AML: Evaluation of the Impact of Transitioned Outpatient Chemotherapy in an Oncology Care Model Setting

Leila Jafari, Jubair Hussain, Ravi Krishnadasan, MD, Keri R Maher, DO, Faiz Anwer, MD, Emad Elquza, MD MBA, Christopher Campen, PharmD, Lauren Sanders, PharmD, Alyssa Henglefelt, PharmD, Alicia Ortega, PharmD, Ali McBride, PharmD,MS

Blood (2019) 134 (Supplement_1): 2153.

https://doi.org/10.1182/blood-2019-132121

Published: 2019

Journal Articles

Adoptive Therapy with Cord Blood Regulatory T Cells Can Treat Graft Vs Host Disease

Hongbing Ma, MD PhD, Ke Zeng, MD PhD, Mitsutaka Nishimoto, MD PhD, Mi-Ae Lyu, PhD, Meixian Huang, Swaminathan P. Iyer, MD, Simrit Parmar, MBBS

Blood (2019) 134 (Supplement_1): 1940.

https://doi.org/10.1182/blood-2019-129395

Published: 2019

Journal Articles

Augmenting the Patient Experience: Therapeutic Arts Interventions for Patients Undergoing Chemotherapy/Infusion

Fred Schiffman, MD, Cynthia S Peng, BS, Anna C Delamerced, BA, Lauren V Ready, MPH, Kevin S Tang, BA, Pamela Yan, BS, Laura L Butterfield, BSN, Alexandra Krupa, RN BSN ACM

Blood (2019) 134 (Supplement_1): 2187.

https://doi.org/10.1182/blood-2019-125265

Published: 2019

Journal Articles

Potential and Realized Cost Savings with the Use of the Biosimilar Grastofil Vs Neupogen

Hishaam Bhimji, BSP, Dean Eurich, PhD, Kerry Mansell, PharmD, MBA, Holly Mansell, PharmD

Blood (2019) 134 (Supplement_1): 2126.

https://doi.org/10.1182/blood-2019-122751

Published: 2019

Journal Articles

Proof of Concept for Repair of Sickle Cell Disease By Non-Myeloablative MHC Disparate T Cell Depleted HSCT Combined with Donor-Derived Veto Cells

Aloukick Kumar Singh, PhD, Elias Schetzen, PhD, Esther BACHAR Lustig, PhD, Wei-Hsin Liu, M.Sc, Raj Kumar Yadav, PhD, Sandeep Kumar Yadav, PhD, Kathryn McGinnis, M.Sc, Yair Reisner, PhD

Blood (2019) 134 (Supplement_1): 1919.

https://doi.org/10.1182/blood-2019-124594

Published: 2019

Journal Articles

Patterns of Care and Predictors of Survival in Adolescents and Young Adults with Hodgkin Lymphoma: A Population-Based Study

Justine M. Kahn, MD MS, Fran Maguire, PhD MPH, Qian Li, MS, Elysia Alvarez, MD MPH, Theresa H.M. Keegan, PhD MS

Blood (2019) 134 (Supplement_1): 2191.

https://doi.org/10.1182/blood-2019-129301

Published: 2019

Journal Articles

RUNX1 Mutation Is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia Receiving Allogeneic Stem Cell Transplantation

Onyee Chan, MD, Chetasi Talati, MD, Hannah H Asghari, MD, Jinming Song, MD PhD, Mohammad Hussaini, MD, Andrew T Kuykendall, MD, David A Sallman, MD, Eric Padron, MD, Rami S. Komrokji, MD, Alan F. List, MD, Jeffrey E. Lancet, MD, Asmita Mishra, MD, Kendra L. Sweet, MD

Blood (2019) 134 (Supplement_1): 2052.

https://doi.org/10.1182/blood-2019-129742

Published: 2019

Journal Articles

Impact of Co-Morbidities on Outcome in a Predominantly Hispanic Population of Hodgkin and Non-Hodgkin Lymphoma Patients

Michelle Janania Martinez, MD, Juan F Garza, MD, Tyler W Snedden, MD, Prathibha Surapaneni, MD, Snegha Ananth, MBBS, Jeremy Rawlings, MD, David J Gregorio, DO, Sushanth Kakarla, MD, Qianqian Liu, PhD, Joel E Michalek, PhD, Adolfo Enrique Diaz, MD

Blood (2019) 134 (Supplement_1): 2204.

https://doi.org/10.1182/blood-2019-129442

Published: 2019

NARROW

Minorities Do Not Have Worse Outcomes for Diffuse Large B Cell Lymphoma (DLBCL) If Optimally Managed

Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia

Outcomes of Patients with Acute Myeloid Leukemia with Myelodysplastic Are Dependent on Diagnostic Criteria and Therapy

Landscape of TP53 Mutations in MPN

VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRD) with or without Rivaroxaban Prophylaxis

Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of CNS Relapse Treated in the Rituximab Era

Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes

WHO-Defined Chronic Myelomonocytic Leukemia-2 (CMML-2) Patients Rapidly Progress to AML Suggesting This Entity Represents a Transitory Clinical State

Choice of Hypomethylating Agent (HMA) for Initial Treatment Does Not Influence Outcome or Survival for Therapy-Related Myeloid Neoplasms (t-MN)

RAS Mutations Are Independently Associated with Decreased Overall Survival and Event-Free Survival in Patients with AML Receiving Induction Chemotherapy

Feasibility of Outpatient High Dose Cytarabine in Patients with Acute Myeloid Leukemia

Implementation of Outpatient High-Dose Cytarabine (HiDAC) for AML: Evaluation of the Impact of Transitioned Outpatient Chemotherapy in an Oncology Care Model Setting

Adoptive Therapy with Cord Blood Regulatory T Cells Can Treat Graft Vs Host Disease

Augmenting the Patient Experience: Therapeutic Arts Interventions for Patients Undergoing Chemotherapy/Infusion

Potential and Realized Cost Savings with the Use of the Biosimilar Grastofil Vs Neupogen

Proof of Concept for Repair of Sickle Cell Disease By Non-Myeloablative MHC Disparate T Cell Depleted HSCT Combined with Donor-Derived Veto Cells

Patterns of Care and Predictors of Survival in Adolescents and Young Adults with Hodgkin Lymphoma: A Population-Based Study

RUNX1 Mutation Is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia Receiving Allogeneic Stem Cell Transplantation

Impact of Co-Morbidities on Outcome in a Predominantly Hispanic Population of Hodgkin and Non-Hodgkin Lymphoma Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only